The project period has been extended until December 31, 2026, with the budget remaining unchanged.

The extension enables Abera to complete and analyze ongoing in vivo studies and prepare for the next phase of development. This work includes scale-up and industrialization of the manufacturing process ahead of the production of material for toxicology studies and a future Phase 1 clinical trial.

During the course of the project, Abera has achieved several important milestones, and the results from completed studies have been encouraging. Several additional in vivo studies are currently ongoing and under analysis. The extension will enable the Company to complete this work while intensifying preparations for the next phase of development.

CEPI’s decision to extend the project provides an opportunity for the organization to continue evaluating the results from the ongoing studies as well as the potential of the BERA vaccine platform within the framework of CEPI’s 100 Days Mission, which aims to accelerate the development of vaccines against future pandemic threats.

“We are pleased with CEPI’s decision to extend the project. The extension enables us to complete important studies, analyze the results, and at the same time prepare manufacturing activities for the next phase of development. CEPI’s continued support for the project is an important validation of the progress achieved so far and provides a strong foundation for advancing both the BERA vaccine platform and our influenza vaccine candidate towards clinical development,” says Maria Alriksson, CEO of Abera Bioscience.